Johnson & Johnson (NYSE:JNJ) Releases FY 2026 Earnings Guidance

Johnson & Johnson (NYSE:JNJ) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 11.050-11.150 for the period, compared to the consensus earnings per share estimate of 11.100. The company issued revenue guidance of $101.0 billion-$101.4 billion, compared to the consensus revenue estimate of $101.3 billion.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Johnson Rice reissued a “buy” rating on shares of Johnson & Johnson in a research report on Monday, August 3rd. The Goldman Sachs Group restated a “buy” rating and issued a $282.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. UBS Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, September 22nd. Guggenheim reiterated a “buy” rating and set a $287.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 7th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a report on Tuesday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $276.22.

Johnson & Johnson Stock Performance

JNJ stock traded down $14.83 during midday trading on Tuesday, reaching $248.90. The company had a trading volume of 16,613,205 shares, compared to its average volume of 7,994,569. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The stock has a 50 day moving average price of $265.89 and a 200 day moving average price of $249.37. Johnson & Johnson has a fifty-two week low of $184.66 and a fifty-two week high of $281.07. The firm has a market capitalization of $599.83 billion, a PE ratio of 28.84, a P/E/G ratio of 2.65 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. The business had revenue of $25.40 billion for the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%. The business’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period in the prior year, the firm earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Analysts anticipate that Johnson & Johnson will post 11.18 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is presently 62.11%.

Insider Buying and Selling

In other news, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares in the company, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 87,569 shares of company stock valued at $23,064,544. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ reported third-quarter adjusted EPS of $2.59, above the $2.53 analyst consensus, while revenue increased 5.9% year over year to approximately $25.4 billion. Johnson & Johnson Q3 earnings report
• Positive Sentiment: Management raised its 2026 outlook, lifting the reported sales midpoint to $101.2 billion and adjusted EPS midpoint to $11.10, supported by Innovative Medicine growth. Johnson & Johnson raises 2026 guidance
• Positive Sentiment: TREMFYA sales and encouraging long-term Crohn’s disease data provide support for JNJ’s pharmaceutical growth strategy, helping offset pressure from Stelara biosimilar competition. TREMFYA Crohn’s disease data
• Positive Sentiment: The company declared a quarterly dividend of $1.34 per share, reinforcing its appeal to income-focused investors. Johnson & Johnson dividend announcement
• Neutral Sentiment: JNJ said it is leaning toward spinning out its hips-and-knees business, a potential long-term restructuring catalyst but also an acknowledgment of challenges within MedTech. J&J hips-and-knees business spinoff
• Negative Sentiment: MedTech growth disappointed, particularly in cardiovascular and surgery markets outside the United States. Investors viewed the segment’s performance as evidence that the business may require further improvement. Investors focus on J&J MedTech
• Negative Sentiment: Reported net income fell sharply and GAAP EPS declined to $0.09 because of charges tied largely to the proposed talc litigation resolution, the Firefly Bio acquisition and the Sail Biomedicines collaboration. Johnson & Johnson quarterly report analysis
• Negative Sentiment: Investors appeared to treat the guidance increase as modest relative to elevated expectations, while new drug deals are expected to pressure 2027 earnings. Broader healthcare weakness and geopolitical disruption affecting device sales added to the selling pressure.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.